Neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein are a key pathological hallmark. See Neurofibrillary Tangles for detailed information.
Alzheimer's Disease is a progressive neurodegenerative disorder affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches. [16]
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 900 280" width="900" height="280">
<defs>
<linearGradient id="preclinicalGrad" x1="0%" y1="0%" x2="100%" y2="0%">
<stop offset="0%" style="stop-color:#E8F5E9;stop-opacity:1" />
<stop offset="100%" style="stop-color:#C8E6C9;stop-opacity:1" />
</linearGradient>
<linearGradient id="mciGrad" x1="0%" y1="0%" x2="100%" y2="0%">
<stop offset="0%" style="stop-color:#FFF9C4;stop-opacity:1" />
<stop offset="100%" style="stop-color:#FFF59D;stop-opacity:1" />
</linearGradient>
<linearGradient id="mildGrad" x1="0%" y1="0%" x2="100%" y2="0%">
<stop offset="0%" style="stop-color:#FFE0B2;stop-opacity:1" />
<stop offset="100%" style="stop-color:#FFCC80;stop-opacity:1" />
</linearGradient>
<linearGradient id="moderateGrad" x1="0%" y1="0%" x2="100%" y2="0%">
<stop offset="0%" style="stop-color:#FFAB91;stop-opacity:1" />
<stop offset="100%" style="stop-color:#FF8A65;stop-opacity:1" />
</linearGradient>
<linearGradient id="severeGrad" x1="0%" y1="0%" x2="100%" y2="0%">
<stop offset="0%" style="stop-color:#EF9A9A;stop-opacity:1" />
<stop offset="100%" style="stop-color:#E57373;stop-opacity:1" />
</linearGradient>
</defs>
<!-- Background -->
<rect x="0" y="0" width="900" height="280" fill="#fafafa" rx="8"/>
<!-- Title -->
<text x="450" y="25" font-family="Arial, sans-serif" font-size="18" font-weight="bold" fill="#37474f" text-anchor="middle">Alzheimer's Disease Progression Timeline</text>
<!-- Timeline axis -->
<line x1="50" y1="200" x2="850" y2="200" stroke="#78909c" stroke-width="2"/>
<!-- Time markers -->
<text x="50" y="220" font-family="Arial, sans-serif" font-size="10" fill="#546e7a" text-anchor="middle">Preclinical</text>
<text x="250" y="220" font-family="Arial, sans-serif" font-size="10" fill="#546e7a" text-anchor="middle">MCI</text>
<text x="450" y="220" font-family="Arial, sans-serif" font-size="10" fill="#546e7a" text-anchor="middle">Mild AD</text>
<text x="650" y="220" font-family="Arial, sans-serif" font-size="10" fill="#546e7a" text-anchor="middle">Moderate AD</text>
<text x="850" y="220" font-family="Arial, sans-serif" font-size="10" fill="#546e7a" text-anchor="middle">Severe AD</text>
<!-- Years -->
<text x="50" y="235" font-family="Arial, sans-serif" font-size="9" fill="#78909c" text-anchor="middle">-20 years</text>
<text x="250" y="235" font-family="Arial, sans-serif" font-size="9" fill="#78909c" text-anchor="middle">-10 years</text>
<text x="450" y="235" font-family="Arial, sans-serif" font-size="9" fill="#78909c" text-anchor="middle">Diagnosis</text>
<text x="650" y="235" font-family="Arial, sans-serif" font-size="9" fill="#78909c" text-anchor="middle">+3 years</text>
<text x="850" y="235" font-family="Arial, sans-serif" font-size="9" fill="#78909c" text-anchor="middle">+8-12 years</text>
<!-- Stage boxes -->
<!-- Preclinical -->
<rect x="20" y="50" width="160" height="130" fill="url(#preclinicalGrad)" rx="8" stroke="#81c784" stroke-width="2"/>
<text x="100" y="75" font-family="Arial, sans-serif" font-size="14" font-weight="bold" fill="#2e7d32" text-anchor="middle">Preclinical</text>
<text x="100" y="95" font-family="Arial, sans-serif" font-size="10" fill="#1b5e20" text-anchor="middle">No symptoms</text>
<text x="100" y="115" font-family="Arial, sans-serif" font-size="9" fill="#1b5e20" text-anchor="middle">• Amyloid accumulation</text>
<text x="100" y="130" font-family="Arial, sans-serif" font-size="9" fill="#1b5e20" text-anchor="middle">• Tau pathology begins</text>
<text x="100" y="145" font-family="Arial, sans-serif" font-size="9" fill="#1b5e20" text-anchor="middle">• Subtle memory changes</text>
<text x="100" y="165" font-family="Arial, sans-serif" font-size="9" fill="#1b5e20" text-anchor="middle">Biomarkers: A+/T-</text>
<!-- MCI -->
<rect x="190" y="50" width="160" height="130" fill="url(#mciGrad)" rx="8" stroke="#fdd835" stroke-width="2"/>
<text x="270" y="75" font-family="Arial, sans-serif" font-size="14" font-weight="bold" fill="#f57f17" text-anchor="middle">MCI due to AD</text>
<text x="270" y="95" font-family="Arial, sans-serif" font-size="10" fill="#f9a825" text-anchor="middle">Mild cognitive decline</text>
<text x="270" y="115" font-family="Arial, sans-serif" font-size="9" fill="#f9a825" text-anchor="middle">• Memory lapses</text>
<text x="270" y="130" font-family="Arial, sans-serif" font-size="9" fill="#f9a825" text-anchor="middle">• Word-finding difficulty</text>
<text x="270" y="145" font-family="Arial, sans-serif" font-size="9" fill="#f9a825" text-anchor="middle">• Complex tasks impaired</text>
<text x="270" y="165" font-family="Arial, sans-serif" font-size="9" fill="#f9a825" text-anchor="middle">Biomarkers: A+/T+</text>
<!-- Mild AD -->
<rect x="360" y="50" width="160" height="130" fill="url(#mildGrad)" rx="8" stroke="#ff9800" stroke-width="2"/>
<text x="440" y="75" font-family="Arial, sans-serif" font-size="14" font-weight="bold" fill="#e65100" text-anchor="middle">Mild AD</text>
<text x="440" y="95" font-family="Arial, sans-serif" font-size="10" fill="#ef6c00" text-anchor="middle">Early dementia</text>
<text x="440" y="115" font-family="Arial, sans-serif" font-size="9" fill="#ef6c00" text-anchor="middle">• Memory loss (recent events)</text>
<text x="440" y="130" font-family="Arial, sans-serif" font-size="9" fill="#ef6c00" text-anchor="middle">• Personality changes</text>
<text x="440" y="145" font-family="Arial, sans-serif" font-size="9" fill="#ef6c00" text-anchor="middle">• Disorientation to time</text>
<text x="440" y="165" font-family="Arial, sans-serif" font-size="9" fill="#ef6c00" text-anchor="middle">MMSE: 20-26</text>
<!-- Moderate AD -->
<rect x="530" y="50" width="160" height="130" fill="url(#moderateGrad)" rx="8" stroke="#ff5722" stroke-width="2"/>
<text x="610" y="75" font-family="Arial, sans-serif" font-size="14" font-weight="bold" fill="#bf360c" text-anchor="middle">Moderate AD</text>
<text x="610" y="95" font-family="Arial, sans-serif" font-size="10" fill="#d84315" text-anchor="middle">Middle-stage dementia</text>
<text x="610" y="115" font-family="Arial, sans-serif" font-size="9" fill="#d84315" text-anchor="middle">• Significant memory gaps</text>
<text x="610" y="130" font-family="Arial, sans-serif" font-size="9" fill="#d84315" text-anchor="middle">• Personality/behavior changes</text>
<text x="610" y="145" font-family="Arial, sans-serif" font-size="9" fill="#d84315" text-anchor="middle">• Need help with daily activities</text>
<text x="610" y="165" font-family="Arial, sans-serif" font-size="9" fill="#d84315" text-anchor="middle">MMSE: 10-19</text>
<!-- Severe AD -->
<rect x="700" y="50" width="160" height="130" fill="url(#severeGrad)" rx="8" stroke="#e53935" stroke-width="2"/>
<text x="780" y="75" font-family="Arial, sans-serif" font-size="14" font-weight="bold" fill="#b71c1c" text-anchor="middle">Severe AD</text>
<text x="780" y="95" font-family="Arial, sans-serif" font-size="10" fill="#c62828" text-anchor="middle">Late-stage dementia</text>
<text x="780" y="115" font-family="Arial, sans-serif" font-size="9" fill="#c62828" text-anchor="middle">• Loss of verbal communication</text>
<text x="780" y="130" font-family="Arial, sans-serif" font-size="9" fill="#c62828" text-anchor="middle">• Unable to recognize family</text>
<text x="780" y="145" font-family="Arial, sans-serif" font-size="9" fill="#c62828" text-anchor="middle">• Total care dependency</text>
<text x="780" y="165" font-family="Arial, sans-serif" font-size="9" fill="#c62828" text-anchor="middle">MMSE: <10</text>
<!-- Biomarker note -->
<text x="450" y="260" font-family="Arial, sans-serif" font-size="9" fill="#78909c" text-anchor="middle">A+ = Amyloid positive | T+ = Tau positive | MCI = Mild Cognitive Impairment | MMSE = Mini-Mental State Examination</text>
</svg>
Figure: Typical disease progression in Alzheimer's Disease showing clinical stages, symptoms, and biomarker changes over time.
Alzheimer's Disease (AD) is the most common neurodegenerative disorder and the leading cause of dementia worldwide, accounting for 60–70% of all dementia cases. First described
by Alois Alzheimer(/researchers/alois-alzheimer) in 1906, AD is a progressive, irreversible brain disorder characterized by the insidious onset of
memory loss, followed by deterioration in language, visuospatial abilities, executive function, and ultimately the capacity for independent living. The disease is
neuropathologically defined by two hallmark lesions: extracellular amyloid-beta ([Aβ) plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated
tau] protein. Synaptic loss is the strongest pathological correlate of cognitive decline, and the disease follows a stereotyped anatomical progression described by Braak staging.
[6]
AD affects over 55 million people globally, with numbers projected to reach 139 million by 2050 as populations age. The global economic burden exceeded $1.3 trillion in 2019 and continues to rise. The approval of anti-amyloid antibodies — lecanemab in 2023 and donanemab in 2024 — represented the first disease-modifying therapies, partially validating the amyloid hypothesis after decades of clinical failures, while simultaneously highlighting the complexity of AD pathogenesis and the need for multi-targeted approaches
[1].
AD progresses through distinct clinical stages, each characterized by specific biomarker changes and clinical manifestations. Understanding this continuum is essential for early detection, diagnosis, and therapeutic intervention.
| Stage | Typical Duration | Key Features | Biomarkers |
|---|---|---|---|
| Preclinical | 10-20 years | Normal cognition, amyloid accumulation | Aβ PET +, CSF Aβ42 ↓ |
| MCI due to AD | 5-10 years | Memory complaints, objective deficits | Aβ PET +, tau ↑ |
| Mild Dementia | 2-10 years | Memory + other domains impaired | FDG PET ↓ |
| Moderate Dementia | 2-8 years | Personality changes, daily assistance | Widespread atrophy |
| Severe Dementia | 1-5 years | Loss of communication, motor issues | Severe neurodegeneration |
Legend: ↑ = elevated; ↓ = decreased; + = positive/abnormal
The ATN (Amyloid/Tau/Neurodegeneration) framework categorizes AD by biomarker status:
The typical time from preclinical AD to death is approximately 20-30 years, though this varies significantly between individuals. Key considerations:
Understanding disease progression informs therapeutic strategies:
Several emerging biomarkers show promise for improved AD diagnosis and monitoring:
Alzheimer's disease currently affects more than 55 million people globally, and demographic aging is projected to drive this burden substantially higher over coming decades [1].
Recent comprehensive reviews also emphasize that Alzheimer's disease is the leading cause of dementia and a dominant contributor to disability, dependency, and long-term care demand
[3][4].
The economic burden is already measured in the trillions of dollars annually, supporting early diagnosis, biomarker-enabled stratification, and prevention-oriented trial design as public-health priorities [1].
Alzheimer's disease affects women disproportionately, representing a critical dimension of disease epidemiology that has significant implications for research, clinical care, and public health planning [1].
Prevalence and Lifetime Risk: Women constitute approximately two-thirds of Alzheimer's disease cases worldwide. This disparity is partly due to the fact that women live longer on average, but epidemiological studies indicate that age-adjusted risk remains higher in women even after controlling for longevity [1]. The higher prevalence translates to women representing roughly 60% of the 6.5 million Americans living with Alzheimer's disease [3].
Biological Mechanisms: Several biological factors contribute to sex differences in AD risk:
Apolipoprotein E (APOE): The APOE ε4 allele confers a higher risk in women compared to men. Women with one copy of APOE ε4 have approximately 4-times the risk of developing AD compared to 2-times in men with the same genotype [1].
Hormonal Factors: Estrogen has complex effects on brain health. See Estrogen Signaling in Neurodegeneration for detailed mechanisms.. The rapid decline in estrogen during menopause may accelerate amyloid-beta accumulation and impair neuronal energy metabolism. Women's loss of protective estrogen effects post-menopause is hypothesized to contribute to increased vulnerability [1].
Immune Response: Women generally mount stronger innate and adaptive immune responses, which may be a double-edged sword. While this provides better resistance to infections, it may also contribute to increased neuroinflammation and autoimmune reactivity in the brain [1].
Disease Progression: Women with Alzheimer's disease tend to exhibit more rapid cognitive decline compared to men, even after adjusting for age and education [1]. Neuroimaging studies reveal that women show greater amyloid burden at equivalent clinical stages, suggesting either faster accumulation or different threshold for clinical expression [4].
Treatment Response: Sex differences have been observed in response to certain Alzheimer's therapies. Women may respond differently to cholinesterase inhibitors, the first-line symptomatic treatments, with some studies suggesting reduced efficacy in women [1]. Additionally, sex-specific responses to emerging anti-amyloid immunotherapies are being actively investigated in clinical trials [5].
Research Implications: Understanding sex differences is essential for personalized medicine approaches in Alzheimer's disease. The Women's Brain Project and similar initiatives advocate for sex-specific analysis in all AD research to ensure findings are applicable to both sexes. Future clinical trials must stratify results by sex to identify sex-specific therapeutic targets and optimize treatment strategies for women, who represent the majority of patients [1][59].
History
The history of Alzheimer's Disease begins in November 1901, when German psychiatrist Alois Alzheimer admitted a 51-year-old woman named Auguste Deter to the Frankfurt Psychiatric Hospital. She presented with paranoia, progressive memory disturbance, disorientation, aggression, and confusion — symptoms that did not fit established psychiatric categories of the time [2].
Following Auguste Deter's death on April 8, 1906, Alzheimer had her brain transported to Emil Kraepelin's laboratory in Munich. Using the newly developed Bielschowsky silver stain, Alzheimer and two Italian physicians identified the two pathological hallmarks that would define the disease: extracellular amyloid plaques and intracellular neurofibrillary tangles. On November 3, 1906, Alzheimer presented his findings — "A Peculiar Severe Disease Process of the Cerebral cortex" — at the 37th Meeting of South-West German Psychiatrists in Tübingen. Remarkably, the presentation generated little interest from attendees
[3].
Between 1906 and 1909, Kraepelin included Auguste Deter's case history in the 8th edition of his landmark textbook Psychiatrie, naming the condition "Alzheimer's Disease." Alzheimer published three additional cases in 1909 and a "plaque-only" variant in 1911. Alzheimer died in 1915 at age 51, long before his name became a household word [4].
Key milestones in AD research include:
blood-brain barrier breakdown, cerebral amyloid angiopathy, and neurovascular unit dysfunction contribute to AD pathogenesis, particularly in APOE4 accelerates [/entities/blood-brain-barrier|blood-brain-barrier degradation. The glymphatic system — the brain's waste clearance pathway active during sleep — is impaired in AD, reducing Aβ clearance. Cerebral small vessel disease frequently co-occurs with AD and contributes to cognitive decline through additive or synergistic mechanisms [21].
AD diagnosis integrates clinical evaluation, neuropsychological testing, and increasingly, biomarker confirmation. The 2024 Revised Criteria from the Alzheimer's Association Workgroup (Jack et al., 2024) redefine AD as a biological entity diagnosed by biomarkers, with clinical staging as a separate dimension. [7]
The AT(N) classification system categorizes AD biomarkers into three pathological dimensions:
| Category | Biomarker | Method |
|---|---|---|
| A (Amyloid) | CSF Aβ42/40 ratio; amyloid PET (florbetapir, florbetaben, flutemetamol) | Lumbar puncture; PET imaging |
| T (Tau | CSF p-tau181, p-tau217; tau PET (18Fflortaucipir, 18FMK-6240) | Lumbar puncture; PET imaging |
| N (Neurodegeneration) | CSF NfL, total tau; structural MRI (hippocampal atrophy); FDG-PET (hypometabolism) | LP; blood test; MRI; PET |
A biomarker-positive status in both A and T categories (A+T+) defines biological AD regardless of clinical symptoms [22].
Blood-based biomarkers represent a transformative advance in AD diagnosis. In May 2025, the FDA approved the first in vitro diagnostic device for AD — the Lumipulse G
p-tau217/Aβ1-42 Plasma Ratio — with 91.7% concordance with amyloid PET and CSF biomarkers. Plasma p-tau217 achieves AUCs of 0.93–0.96 for detecting AD pathology, approaching
the accuracy of CSF biomarkers at a fraction of the cost. This development promises to dramatically expand access to AD biomarker testing beyond specialized centers [23].
Additional blood biomarkers under investigation include plasma Aβ42/40 ratio, GFAP (astrocyte reactivity), and NfL (neurodegeneration) [24].
| Drug | Class | Indication | Mechanism |
|---|---|---|---|
| Donepezil (Aricept) | Cholinesterase inhibitor | Mild–severe AD | Enhances acetylcholine signaling at surviving synapses |
| Rivastigmine (Exelon) | Cholinesterase inhibitor | Mild–moderate AD | Dual AChE/BuChE inhibition |
| Galantamine(/treatments/galantamine) (Razadyne) | Cholinesterase inhibitor | Mild–moderate AD | AChE inhibition + nicotinic receptor allosteric modulation |
| Memantine (Namenda) | NMDA receptor] antagonist | Moderate–severe AD | Reduces excitotoxicity from excessive glutamate signaling |
| Suvorexant (Belsomra) | Orexin receptor antagonist | AD-associated insomnia | Modulates sleep/wake circuitry |
| Brexpiprazole (Rexulti) | Atypical antipsychotic | AD-associated agitation | D2/5-HT1A partial agonist |
| Drug | Target | Status | Key Results |
|---|---|---|---|
| Lecanemab/treatments/lecanemab) (Leqembi | Aβ protofibrils | FDA full approval (2023) | 27% slowing of cognitive decline over 18 months (CLARITY AD); maintenance dosing approved Jan 2025; subcutaneous Home injection (LEQEMBI IQLIK) approved Aug 2025 |
| **Donanemab/treatments/donanemab) (Kisunla) | Aβ N3pG plaques | FDA approved (2024) | 35% slowing in low/medium tau subgroup; first therapy designed for discontinuation after plaque clearance (TRAILBLAZER-ALZ 2) |
| Aducanumab(/treatments/aducanumab) (Aduhelm) | Aβ aggregates | Withdrawn (2024) | Controversial accelerated approval in 2021; voluntarily withdrawn from market |
ARIA (Amyloid-Related Imaging Abnormalities) — cerebral edema (ARIA-E) and microhemorrhages (ARIA-H) — remains the primary safety concern with anti-amyloid immunotherapy, occurring in 20–35% of patients and more frequently in APOE4 trial, BIIB080/IONIS-MAPTRx (tau-lowering antisense oligonucleotide, bepranemab, semorinemab
The median survival from symptom onset is 8–10 years, though this varies widely (3–20 years) based on age at onset, genetics, comorbidities, and access to care. Younger-onset patients typically survive longer from diagnosis but experience more rapid cognitive decline. The leading causes of death are aspiration pneumonia, cardiovascular disease, and other complications of immobility and debility
[1].
Disease-modifying therapies (lecanemab, donanemab) have demonstrated statistically significant slowing of cognitive decline, but the clinical meaningfulness of the effect size (27–35% slowing) remains debated. Combination approaches targeting multiple pathways are increasingly viewed as necessary for substantial clinical impact [2].
Despite decades of research and the recent approval of anti-amyloid immunotherapies, fundamental questions about Alzheimer's Disease biology remain unanswered. The field is at an inflection point: first-generation disease-modifying therapies show modest efficacy, but the path to truly effective treatment requires resolving these open questions.
The amyloid cascade hypothesis posits that amyloid-beta accumulation initiates a pathological cascade leading to tau pathology, neuroinflammation, synaptic loss, and neuronal death. While anti-amyloid antibodies (lecanemab, donanemab) have demonstrated statistically significant slowing of cognitive decline, the modest effect size (25-35% slowing) and significant side effects have intensified debate.[2]
Unresolved questions:
While amyloid deposition begins decades before symptoms, tau hyperphosphorylation and spreading correlate more closely with cognitive decline. Yet no tau-targeted therapy has received FDA approval.[4]
Unresolved questions:
Evidence suggests differential expression of amyloid and tau pathology across racial and ethnic groups, despite similar clinical symptoms, leading to higher rates of screen failure and lower inclusion rates among non-White populations in clinical trials.[5]
Unresolved questions:
For a comprehensive cross-disease analysis, see Research Priorities in Neurodegenerative Disease.
The study of Alzheimer's Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration/mechanisms) and continues to drive therapeutic development [3].
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [4].
The following questions are prioritized for near-term experimental and translational work. They are intended to guide hypothesis generation, preclinical design, and trial strategy.
Auto-updated from bioRxiv/medRxiv ingest pipeline for papers published since 2026-01-31.
Auto-updated from bioRxiv/medRxiv ingest pipeline for papers published since 2026-01-31.
10.1101/2024.06.04.597496)10.64898/2026.02.03.26345515)10.1101/2025.10.24.25338613)10.64898/2026.01.31.26344775)10.64898/2026.02.02.26345372)These entries are preprints and should be interpreted alongside peer-reviewed evidence on Alzheimer's Disease.
The blood-brain barrier (BBB) plays a critical role in maintaining brain homeostasis, and its dysfunction is increasingly recognized as a key contributor to Alzheimer's disease pathogenesis. The receptor for advanced glycation endproducts (RAGE) is central to this process [1].
RAGE is a pattern recognition receptor that binds to advanced glycation endproducts (AGEs), amyloid-beta (Aβ) fibrils, and other misfolded proteins [2]. In Alzheimer's disease:
The interaction between RAGE and misfolded proteins creates a vicious cycle: Aβ binding to RAGE increases inflammation, which promotes more Aβ production and aggregation.
Several therapeutic approaches aim to restore BBB function and reduce RAGE-mediated damage:
RAGE Inhibitors: Small molecule inhibitors (e.g., FPS-ZM1, PF-04494700) block RAGE-Aβ interaction and have shown promise in preclinical models [7]
LRP1 Enhancers: Low-density lipoprotein receptor-related protein 1 (LRP1) mediates Aβ efflux from the brain. Strategies to upregulate LRP1 expression improve Aβ clearance [8]
Pericyte Protection: PDGFR-β agonists and pericyte survival factors help maintain BBB integrity [9]
Tight Junction Stabilizers: Matrix metalloproteinase (MMP) inhibitors and anti-inflammatory agents help preserve tight junction proteins [10]
BBB-Penetrant Drugs: Development of drugs that can cross the BBB, including GLP-1 receptor agonists and antibody fragments [11]
Gene Therapy Approaches: Viral vector-mediated delivery of Aβ-degrading enzymes and transport protein genes [12]
For detailed information on BBB pathophysiology and therapeutic approaches, see Blood-Brain Barrier Breakdown in Alzheimer's Disease.
MAPT-Mutant Neurons - Tau protein mutations in neuronal models
Hippocampal Neurogenesis - Adult neurogenesis and its decline in AD
Pittsburgh Compound B (PiB) - Amyloid PET imaging biomarker
The following studies were newly indexed in PubMed between 2026-01-30 and 2026-03-01 and are relevant to Alzheimer's Disease:
Recent studies in Alzheimer's disease emphasize immune-system dysregulation, biomarker staging in communities, and endosomal-trafficking genetics as convergent translational priorities.
Recent bioRxiv preprints (February 2026) have identified novel mechanisms in Alzheimer's disease:
Nicotinic Acetylcholine Receptor Subtypes (Feb 2026): A study on co-activation of selective nicotinic acetylcholine receptor subtypes demonstrates their requirement for neuroprotection in Alzheimer's disease. This research expands on the cholinergic hypothesis by identifying specific receptor combinations that may lead to more effective therapeutic strategies.[59]
MAPT V337M Phenotyping (Feb 2026): Multi-omic phenotyping of MAPT V337M neurons reveals early changes in axonogenesis and tau phosphorylation. This provides important insights into how tau mutations lead to neurodegeneration and identifies potential early intervention points.[60]
Recent research in 2026 has yielded several important findings advancing our understanding of Alzheimer's Disease:
Microglial Biology: Brown et al.[17] provide a comprehensive review of microglial phagocytosis in Alzheimer's Disease, examining how these immune cells clear Amyloid-Beta plaques and the implications for therapeutic strategies.
Immune Dysfunction: Butovsky et al.[18] explore the role of neuroinflammation and immune system dysregulation in AD pathogenesis, highlighting potential immunomodulatory treatment approaches.
Blood Biomarkers: Gasparini et al.[19] investigate the relationship between kidney function, Alzheimer's blood biomarkers, and dementia risk in older adults.
PET Imaging: Casper and Bolin[20] examine the clinical utility of PET imaging in Alzheimer's Disease diagnosis and monitoring.
Tau Biomarkers: Nelson and Jicha[22] analyze tau biomarker-based diagnosis and the anti-Amyloid-Beta therapeutic window.
Novel Therapeutic Approaches: Yen et al.[26] investigate lymphovenous anastomosis as a novel surgical approach to address brain lymphatic dysfunction in Alzheimer's Disease.
Recent advances in Alzheimer's disease research (2026):
Alzheimer's disease is the most common cause of dementia worldwide, affecting over 55 million people globally. The disease is characterized by progressive memory loss, cognitive decline, and behavioral changes, with neuropathological hallmarks including amyloid-beta plaques, neurofibrillary tangles composed of hyperphosphorylated tau protein, synaptic loss, and neuronal death.
Despite decades of research, the exact cause of AD remains incompletely understood, though the amyloid hypothesis has dominated therapeutic development. The failure of many amyloid-targeting therapies in clinical trials has prompted reconsideration of disease mechanisms and the need for earlier intervention, precision medicine approaches, and combination therapies.
Current treatment strategies include:
The identification of genetic risk factors (APOE4, TREM2, etc.) and biomarkers (Aβ42, tau, p-tau) has improved early detection and risk stratification. Lifestyle modifications including cognitive engagement, physical exercise, cardiovascular risk management, and social engagement may reduce risk or delay onset.
Future directions include:
Continued investment in basic research, clinical trials, and biomarker development is essential to achieve the goal of effective prevention and treatment for Alzheimer's disease.
Alzheimer's Association. 2024 Alzheimer's Disease facts and figures. Alzheimer's & Dementia (2024)
Knopman et al., Alzheimer's Disease. Nature Reviews Disease Primers (2021)
Long and Holtzman, Alzheimer's Disease pathobiology and treatment. Cell (2019)
van Dyck et al., Lecanemab in Early Alzheimer's Disease. NEJM (2023)
Sims et al., Donanemab in Early Symptomatic Alzheimer's Disease. JAMA (2023)
Jack et al., NIA-AA Research Framework. Alzheimer's & Dementia (2018)
Kimura et al., Immune checkpoint TIM-3 regulates microglia and Alzheimer's Disease (2025)
Physical exercise as a non-pharmacological strategy to enhance glymphatic function (2026 Jun)
Lemere et al., Immune dysfunction in Alzheimer's Disease (2026)
Updated: 2026-03-02 06:03 (UTC)
Brown et al., Microglial phagocytosis in Alzheimer's Disease. Nature Reviews Neurology (2026)
Butovsky et al., Immune dysfunction in Alzheimer's Disease. Nature Neuroscience (2026)
Nelson & Jicha, Tau Biomarker-Based Diagnosis of Alzheimer's Disease. Neurology (2026)
Bray et al., Alzheimer's Disease-Relevant Biomarker Elevations in Psychosis. JAMA Psychiatry (2026)
Xu J et al., Decoding the educational impact on Alzheimer's risk. Lancet 2026. ↩︎
Škorvagová A et al., Hypoperfusion in early-phase amyloid PET. Alzheimer's & Dementia 2026. ↩︎
Son S et al., Amyloid-β aggregates induce vasculopathy. Nature Neuroscience 2026. ↩︎
Gojani EG et al., Serotonergic Psychedelics as Epigenetic Modulators. Alzheimer's & Dementia 2026. ↩︎
Reddy CS et al., NLRP3-driven neuroinflammation in AD. Molecular Neurobiology 2026. ↩︎
Dar SA et al., Early Diagnosis of Alzheimer's. JAD 2026. ↩︎
Titeca J et al., Plasma p-tau217 and APOE-ε4. Alzheimer's & Dementia 2026. ↩︎